4D Molecular Therapeutics (FDMT) Change in Accured Expenses (2020 - 2026)

4D Molecular Therapeutics (FDMT) has reported Change in Accured Expenses for 7 consecutive years, with -$4.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 78.33% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at $6.3 million (down 3.94% YoY), while the FY2025 annual figure was $8.2 million, up 24.95% from the prior year.
• Change in Accured Expenses slipped to -$4.1 million in Q1 2026 per FDMT's latest filing, from $2.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $8.1 million in Q3 2024 and bottomed at -$4.1 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $965235.3 across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 240.75% — and 2024, when it slumped 218.48%.
• 4D Molecular Therapeutics' Change in Accured Expenses stood at $1.8 million in 2022, then climbed by 9.54% to $2.0 million in 2023, then plunged by 218.48% to -$2.4 million in 2024, then soared by 200.25% to $2.4 million in 2025, then slumped by 273.82% to -$4.1 million in 2026.
• Business Quant data shows FDMT's Change in Accured Expenses at -$4.1 million in Q1 2026, $2.4 million in Q4 2025, and $5.0 million in Q3 2025.